中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 8
Aug.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(8): 1825-1831

Value of serum PreS1 in early prediction of HBsAg clearance after IFN-α treatment in children with HBeAg-positive chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2023.08.010
  • 1.

    Peking University 302 Clinical Medical School, Beijing 100191, China

  • 2.

    Department of Liver Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China

Research funding:

the National Science and Technology Major Project of the Infectious Diseases (2018ZX10301404);

Beijing Science and Technology Program (Z201100005520048);

the Capital Clinical Diagnosis and Treatment Technology Research and Translational Application Program (Z201100005520048)

More Information
  • Corresponding author: ZHANG Min, gcmw2001@163.com (ORCID: 0000-0003-2497-6748)
  • Received Date: 2022-12-07
  • Accepted Date: 2023-01-16
  • Published Date: 2023-08-20
    Abstract
  •   Objective  To investigate the value of PreS1 level in predicting HBsAg clearance in children with HBeAg-positive chronic hepatitis B (CHB) after 48 weeks of IFN-α treatment.  Methods  A total of 88 children with HBeAg-positive CHB, aged 1-16 years, who received 48 weeks of IFN-α treatment from June 2016 to January 2020 were enrolled. HBsAg quantification (qHBsAg), HBV DNA quantification, and alanine aminotransferase were measured every three months, and magnetic particle chemiluminescence immunoassay (double-antibody sandwich) was used to measure the level of PreS1. According to whether HBsAg clearance was achieved at the end of IFN-α treatment for 48 weeks, the 88 children were divided into HBsAg clearance group with 17 children and non-HBsAg clearance group with 71 children. The Mann-Whitney U test was used for comparison of quantitative data between the two groups, and the chi-square test or the Fisher's exact test was used for comparison of qualitative data between the two groups. The Spearman rank correlation test was used to evaluate the correlation of PreS1 level with other biomarkers, and the area under the ROC curve (AUC) was used to investigate the value of different markers in predicting HBsAg clearance at the end of 48-week IFN-α treatment.  Results  PreS1 level was positively correlated with the serum levels of qHBsAg and HBV DNA (r=0.912 and 0.535, both P < 0.05), and baseline PreS1/qHBsAg ratio (AUC=0.694) had a better value than PreS1 level (AUC=0.530) and qHBsAg level (AUC=0.514) in predicting HBsAg clearance at week 48. PreS1 level (AUC=0.867, P < 0.001) and the reduction in PreS1/qHBsAg ratio (AUC=0.800, P=0.002) at week 12 of treatment had a good value in predicting HBsAg clearance at week 48. PreS1 level, qHBsAg level, and HBV DNA at week 24 of treatment could effectively predict HBsAg clearance at week 48, with AUCs of 0.917, 0.949, and 0.762, respectively (all P < 0.001).  Conclusion  Serum PreS1 level and the reduction in PreS1/qHBsAg ratio at week 12 of treatment can be used as candidate markers for predicting HBsAg clearance in children with CHB during IFN-α treatment.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    BRAKENHOFF SM, de KNEGT RJ, OLIVEIRA J, et al. Levels of antibodies to hepatitis B core antigen are associated with liver inflammation and response to peginterferon in patients with chronic hepatitis B[J]. J Infect Dis, 2022, 227(1): 113-122. DOI: 10.1093/infdis/jiac210.
    [2]
    LIU YH, LI H, YAN XH, et al. Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B[J]. J Viral Hepat, 2019, 26(Suppl 1): 69-76. DOI: 10.1111/jvh.13154.
    [3]
    FAN HM, LIN LP, JIA SJ, et al. Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B[J]. J Viral Hepat, 2019, 26(Suppl 1): 77-84. DOI: 10.1111/jvh.13165.
    [4]
    PAN J, WANG HY, YAO TT, et al. Clinical predictors of functional cure in children 1-6 years-old with chronic hepatitis B[J]. J Clin Transl Hepatol, 2022, 10(3): 405-411. DOI: 10.14218/JCTH.2021.00142.
    [5]
    ZHU SS, DONG Y, XU ZQ, et al. A retrospective study on HBsAg clearance rate after antiviral therapy in children with HBeAg-positive chronic hepatitis B aged 1-7 years[J]. Chin J Hepatol, 2016, 24(10): 738-743. DOI: 10.3760/cma.j.issn.1007-3418.2016.10.005.

    朱世殊, 董漪, 徐志强, 等. 1~7岁慢性乙型肝炎HBeAg阳性儿童经抗病毒治疗HBsAg清除率的回顾性研究[J]. 中华肝脏病杂志, 2016, 24(10): 738-743. DOI: 10.3760/cma.j.issn.1007-3418.2016.10.005.
    [6]
    WANG LM, ZHAO JF, LIU JY, et al. Long-term benefits of interferon-α therapy in children with HBeAg-positive immune-active chronic hepatitis B[J]. J Viral Hepat, 2021, 28(11): 1554-1562. DOI: 10.1111/jvh.13598.
    [7]
    REN Y, BIAN DD, LIANG C, et al. Predictive value of serum sphingolipids combined with HBsAg quantification in HBsAg clearance of chronic hepatitis B patients treated with nucleos(t)ide analog add-on pegylated interferon α[J]. Translat Med J, 2023, 12(1): 15-21. DOI: 10.3969/j.issn.2095-3097.2023.01.004.

    任艳, 卞丹丹, 梁晨, 等. 血清鞘脂联合定量HBsAg对核苷(酸)类似物经治慢性乙型肝炎患者加用聚乙二醇干扰素α后HBsAg阴转的预测价值[J]. 转化医学杂志, 2023, 12(1): 15-21. DOI: 10.3969/j.issn.2095-3097.2023.01.004.
    [8]
    ZHONG YW, SHI YM, CHU F, et al. Prediction for HBsAg seroconversion in children with chronic hepatitis B[J]. BMC Infect Dis, 2021, 21(1): 1211. DOI: 10.1186/s12879-021-06883-1.
    [9]
    WANG WX, JIA R, GAO YY, et al. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients[J]. Front Immunol, 2022, 13: 894410. DOI: 10.3389/fimmu.2022.894410.
    [10]
    WU WK, YUAN XJ, ZHANG WL, et al. Clinical significance of novel biomarkers to predict the natural course of hepatitis B infection[J]. Front Public Health, 2022, 10: 1037508. DOI: 10.3389/fpubh.2022.1037508.
    [11]
    RINKER F, BREMER CM, SCHRÖDER K, et al. Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon Alfa-2a[J]. Liver Int, 2020, 40(2): 324-332. DOI: 10.1111/liv.14298.
    [12]
    ZHU XJ, GONG QM, YU DM, et al. Early serum hepatitis B virus large surface protein level: A stronger predictor of virological response to peginterferon Alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B[J]. J Clin Virol, 2013, 57(4): 318-322. DOI: 10.1016/j.jcv.2013.04.003.
    [13]
    WANG NY, ZHANG D, ZHAO W, et al. Hepatitis B virus large surface protein in serum as a candidate biomarker for evaluating hepatitis B virus infection[J]. Clin Biochem, 2011, 44(14-15): 1199-1204. DOI: 10.1016/j.clinbiochem.2011.07.002.
    [14]
    LIU C, WU WN, SHANG HY, et al. Prediction value of serum HBV large surface protein in different phases of HBV infection and virological response of chronic hepatitis B patients[J]. Clin Chimica Acta, 2018, 481: 12-19. DOI: 10.1016/j.cca.2018.02.015.
    [15]
    PFEFFERKORN M, SCHOTT T, BÖHM S, et al. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B[J]. J Hepatol, 2021, 74(2): 283-292. DOI: 10.1016/j.jhep.2020.08.039.
    [16]
    PFEFFERKORN M, BÖHM S, SCHOTT T, et al. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers[J]. Gut, 2018, 67(11): 2045-2053. DOI: 10.1136/gutjnl-2017-313811.
    [17]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [18]
    SCHEUER PJ. Classification of chronic viral hepatitis: A need for reassessment[J]. J Hepatol, 1991, 13(3): 372-374. DOI: 10.1016/0168-8278(91)90084-0.
    [19]
    CUI AX, DOU XG, DING Y. Antiviral therapy for pregnant women and children with chronic HBV infection[J]. J Clin Hepatol, 2022, 38(11): 2448-2451. DOI: 10.3969/j.issn.1001-5256.2022.11.003.

    崔傲雪, 窦晓光, 丁洋. 慢性HBV感染孕妇和儿童的抗病毒治疗药物选择及疗效评价[J]. 临床肝胆病杂志, 2022, 38(11): 2448-2451. DOI: 10.3969/j.issn.1001-5256.2022.11.003.
    [20]
    CLEMENTE MG, ANTONUCCI R, SOTGIU G, et al. Present and future management of viral hepatitis B and C in children[J]. Clin Res Hepatol Gastroenterol, 2020, 44(6): 801-809. DOI: 10.1016/j.clinre.2020.02.010.
    [21]
    YAN H, ZHONG GC, XU GW, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J]. eLife, 2012, 1: e00049. DOI: 10.7554/eLife.00049.
    [22]
    BIAN YJ, ZHANG Z, SUN ZC, et al. Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice[J]. Hepatology, 2017, 66(4): 1067-1082. DOI: 10.1002/hep.29239.
    [23]
    ZHUANG H. Clinical significance of determining the serum levels of large, middle, and small hepatitis B virus surface proteins[J]. J Clin Hepatol, 2022, 38(3): 528-531. DOI: 10.3969/j.issn.1001-5256.2022.03.007.

    庄辉. 血清HBV大、中、小表面蛋白检测的临床意义[J]. 临床肝胆病杂志, 2022, 38(3): 528-531. DOI: 10.3969/j.issn.1001-5256.2022.03.007.
    [24]
    NISHIDA Y, IMAMURA M, TERAOKA Y, et al. Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients[J]. J Viral Hepat, 2021, 28(9): 1304-1311. DOI: 10.1111/jvh.13557.
    [25]
    ZHANG M, LI J, WANG FS. Antiviral therapy and clinical cure for chronic hepatitis B in children: Progress and challenges[J]. Chin J Hepatol, 2021, 29(12): 1218-1223. DOI: 10.3760/cma.j.cn501113-20210628-00303.

    张敏, 李静, 王福生. 儿童慢性乙型肝炎抗病毒治疗与临床治愈: 进展与挑战[J]. 中华肝脏病杂志, 2021, 29(12): 1218-1223. DOI: 10.3760/cma.j.cn501113-20210628-00303.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (341) PDF downloads(36) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return